New study: which first treatment works best for severe aplastic anemia?
NCT ID NCT07338422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two first-line treatments for severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. One treatment is a stem cell transplant from a half-matched donor, and the other is drug therapy that suppresses the immune system. The study will follow 116 people aged 14 to 70 to see which approach leads to better survival and recovery, while also tracking side effects like infections and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for older adults with rare blood disorder: safer transplant regimen under study
- New combo therapy for rare blood disorder shows promise
- Double stem cell transplant could be Game-Changer for rare blood disorder
- New study aims to tame harsh side effects of aplastic anemia therapy
- New transplant recipe may tame severe anemia